SS
BCRX icon

SBI Securities’s BioCryst Pharmaceuticals BCRX Stock Holding History

SBI Securities’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$700 Sell
70
-260
-79% -$2.35K ﹤0.01% 2926
2026
Q1 		$3.14K Buy
330
+295
+843% +$2.29K ﹤0.01% 2233
2025
Q4 		$273 Buy
35
+7
+25% +$51 ﹤0.01% 3109
2025
Q3 		$213 Buy
28
+2
+8% +$17 ﹤0.01% 3295
2025
Q2 		$233 Sell
26
-20
-43% -$186 ﹤0.01% 3259
2025
Q1 		$345 Buy
46
+42
+1,050% +$339 ﹤0.01% 3011
2024
Q4 		$30 Buy
+4
New +$30 ﹤0.01% 3745

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

SBI Securities's BCRX Position: Q2 2026 in Review

SBI Securities reduced its BioCryst Pharmaceuticals (BCRX) stake by 79% in Q2 2026, selling an estimated $2.35K and leaving 70 shares worth $700. The position accounts for ﹤0.01% of the portfolio, ranked #2926.

SBI Securities first reported a position in BCRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.14K in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • SBI Securities held 70 shares of BioCryst Pharmaceuticals worth $700 as of Q2 2026.
  • SBI Securities sold 260 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $2.35K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2926 holding.
  • SBI Securities first reported a position in BioCryst Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's BioCryst Pharmaceuticals position peaked at $3.14K in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.